首页>
外国专利>
Use of caveolin polypeptide or caveolin nucleic acid for treating cell proliferation-associated disorder e.g., cancer such as non-steroid dependent carcinoma, stomach carcinoma or colon carcinoma
Use of caveolin polypeptide or caveolin nucleic acid for treating cell proliferation-associated disorder e.g., cancer such as non-steroid dependent carcinoma, stomach carcinoma or colon carcinoma
Use of caveolin polypeptide (I) or caveolin nucleic acid (II) for treating cell proliferation-associated disorder. Independent claims are also included for the following: (1) identifying (M1) a potential therapeutic agent for use in treatment of a pathology that is related to aberrant expression or aberrant physiological interactions of caveolin-1 polypeptide, involves: (a) contacting a cell expressing caveolin-1 polypeptide and having a property or function ascribable to the polypeptide, with a composition; and (b) determining whether the substance alters the property or function ascribable to the polypeptide. If an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition devoid of the substance, then the substance is identified as a potential therapeutic agent; (2) identifying (M2) a carcinoma in a subject involves: (a) measuring the expression of caveolin-1 nucleic acid in a test population obtained from a subject, where at least one cell in the test population is capable of expressing a caveolin-1 nucleic acid; (b) comparing the expression of the caveolin-1 nucleic acid in a reference cell population comprising at least one cell whose carcinoma stage is known; and (c) identifying a difference in the expression levels of caveolin-1 nucleic acid, if present, in the test cell population and a reference cell population, thereby identifying the carcinoma in the subject; (3) assessing (M3) the efficacy of a treatment of a carcinoma in a subject involves: (a) detecting the expression of caveolin-1 nucleic acid in a test cell population obtained from the subject undergoing the treatment, where at least one cell in the test cell population is capable of expressing caveolin-1 nucleic acid; (b) comparing the expression of the nucleic acid sequence to the expression of the nucleic acid sequence in a reference cell population comprising at least one cell whose carcinoma stage is known; and (c) identifying a difference in expression levels of the caveolin-1 sequence, if present, in the test cell population and reference cell population, thereby assessing the efficacy of the treatment of the carcinoma in the subject; (4) identifying (M4) a cancerous tissue involves: (a) contacting a test tissue comprising at least one cell at risk for or affected by cancer with an analyte capable of recognizing caveolin-1 functional group; (b) quantifying the binding of the analyte to the test tissue; (c) comparing the binding of the analyte to the test tissue, to binding of the analyte to a reference tissue which comprises at least one cell whose carcinoma stage is known; and (d) identifying a difference in binding levels of the analyte, if present, in the test tissue and reference tissue, thereby identifying cancerous tissue; (5) a composition (C1) comprising caveolin-1 polypeptide and a carrier; (6) a composition (C2) comprising caveolin-1 nucleic acid and a carrier; and (7) an antibody capable of recognizing caveolin-1 polypeptide.
展开▼
